Noxap (Nitric Oxide)

Nitric Oxide, the active ingredient in Noxap, is a pulmonary vasodilator presented as a gas for inhalation use. It is used to manage pulmonary hypertension and related vascular conditions in adult patients. GNH USA supplies Noxap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Noxap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Noxap is a pulmonary vasodilator that acts on the pulmonary arterial circulation to lower pressure and improve oxygenation.

- Pulmonary arterial hypertension: helps reduce pulmonary artery pressure and improve exercise capacity. - Acute right‑heart strain: supports right‑ventricular function by lowering afterload. - Post‑cardiac surgery pulmonary hypertension: aids in stabilising haemodynamics after operative procedures.

Adverse reactions to inhaled nitric oxide are generally related to its vasodilatory action and the delivery system.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and reddening of the skin, typically short‑lived. - Cough: irritation of the airway during inhalation. - Methemoglobinemia methemoglobinemia: elevated  - Nausea: - Dizziness:

Serious or Rare Side Effects: - Severe hypotension: marked drop in systemic blood pressure. - Rebound pulmonary hypertension: rapid increase in pulmonary pressure after abrupt discontinuation. - Bleeding : - Toxic  g  - Toxic  .

Noxap should be only   g  t  ​   ewline   ewline ​   

-   ewline  ewline  ewline